Liam Ratcliffe
Director/Board Member at DISC MEDICINE, INC.
Net worth: - $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Houston | M | 64 |
Arvinas Operations, Inc.
 Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | 7 years |
| Timothy Shannon | M | 65 |
Halda Therapeutics OpCo, Inc.
Halda Therapeutics LLC
 Halda Therapeutics LLC Medical/Nursing ServicesHealth Services Halda Therapeutics LLC engages in the development of research-stage drugs for novel therapeutic modality. The company is headquartered New Haven, CT.
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | 11 years |
| John Quisel | M | 53 |
Disc Medicine Opco, Inc.
 Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 4 years |
| Andrew Levin | M | 47 | 6 years | |
| Briggs Morrison | M | 65 |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | 11 years |
| Randy Teel | M | 45 | 6 years | |
| Georges Gemayel | M | 64 | 3 years | |
| Steven Hoerter | M | 53 | 6 years | |
| Joanne Bryce | F | 57 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 7 years |
| Kush Parmar | M | 42 | 11 years | |
| Edgar Cale | M | 60 | 5 years | |
| Maxine Gowen | M | 66 | 3 years | |
| Laurie Alsup | M | 70 |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | 5 years |
| Mark Chin | M | 42 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 3 years |
| Karen Ferrante | M | 66 | 15 years | |
| Valerie Morisset | M | 55 | 6 years | |
| Athena Countouriotis | M | 52 |
Recludix Pharma, Inc.
 Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | 4 years |
| Donald Nicholson | M | 67 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 5 years |
| Jakob Loven | M | 46 |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | 3 years |
| William Savage | M | 50 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 4 years |
| Douglas Lankler | M | 58 | 25 years | |
| Ian Taylor | M | 61 | 17 years | |
| Patrick P. Zarrinkar | M | - |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | - |
| Leslie Norwalk | F | 58 |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | 5 years |
| William White | M | 51 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 4 years |
| Kevin Bitterman | M | 47 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 7 years |
| Mona Ashiya | M | 55 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 3 years |
| Sally Susman | F | 62 | 17 years | |
| Brian Hodous | M | - |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | - |
| Derrell Porter | M | 53 | 3 years | |
| Rebecca Velez Frey | F | - |
Halda Therapeutics LLC
Halda Therapeutics LLC Medical/Nursing ServicesHealth Services Halda Therapeutics LLC engages in the development of research-stage drugs for novel therapeutic modality. The company is headquartered New Haven, CT. | - |
| Sandipkumar S. Kapadia | M | 53 | 5 years | |
| Catherine Bovenizer | F | 52 |
Jamanda Ltd.
 Jamanda Ltd. Financial ConglomeratesFinance Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments. | - |
| Wendy Dixon | M | 68 | 4 years | |
| Daniel K. Treiber | M | - |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | - |
| Leyi Wang | M | - |
Halda Therapeutics LLC
Halda Therapeutics LLC Medical/Nursing ServicesHealth Services Halda Therapeutics LLC engages in the development of research-stage drugs for novel therapeutic modality. The company is headquartered New Haven, CT. | - |
| Nancy Whiting | M | 51 |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | 3 years |
| Jessica Sachs | M | 49 | 7 years | |
| Judith Dunn | M | 62 | 3 years | |
| Linda Bain | F | 53 | 4 years | |
| Ron Hunt | M | 59 | 5 years | |
| Alex Blavatnik | M | 59 |
Access Industries LLC
| - |
| Simon Tate | M | 58 | 5 years | |
| Suzanne Johnson | F | 66 | 17 years | |
| Kathleen Borthwick | F | 48 | 3 years | |
| John Green | M | 43 | 6 years | |
| Sean Cassidy | M | 54 |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | - |
| Jay Backstrom | M | 69 |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | 3 years |
| Adam Rosenberg | M | 54 | 4 years | |
| Craig Crews | M | - |
Halda Therapeutics OpCo, Inc.
| - |
| Edward Kennedy | M | 62 | 6 years | |
| Lincoln Benet | M | 60 |
Access Industries LLC
| 18 years |
| Wei Zhao | M | - |
Halda Therapeutics LLC
Halda Therapeutics LLC Medical/Nursing ServicesHealth Services Halda Therapeutics LLC engages in the development of research-stage drugs for novel therapeutic modality. The company is headquartered New Haven, CT. | - |
| Yen Wen Yu | M | - | 4 years | |
| Matthew McAviney | M | - |
Jamanda Ltd.
Jamanda Ltd. Financial ConglomeratesFinance Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments. | - |
| Len Blavatnik | M | 66 |
Access Industries LLC
| 38 years |
| Stuart M. Henderson | M | - | 3 years | |
| Simon Kerry | M | - |
Karus Therapeutics Ltd.
 Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | 18 years |
| Jean Franchi | F | 57 | - | |
| Rebecca Frey | F | - |
Halda Therapeutics OpCo, Inc.
| - |
| Markus Green | M | - | 18 years | |
| Beth Seidenberg | M | 67 |
Jamanda Ltd.
Jamanda Ltd. Financial ConglomeratesFinance Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments. | - |
| Pamela Stephenson | F | 56 | - | |
| Sam Williams | M | - |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | - |
| Dan Becker | M | 49 |
Access Industries LLC
| 5 years |
| Elisabeth A. Bone | M | - |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | 11 years |
| Daniel Martin | M | 49 | 6 years | |
| Jeff Held | M | 55 | 6 years | |
| Martin Edwards | M | 68 |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | - |
| Donald Wagner | M | 60 |
Access Industries LLC
| 14 years |
| Carol Gallagher | M | 59 |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | - |
| Emily Pimblett | F | 40 | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephen P. Squinto | M | 67 | 6 years | |
| Brian MacDonald | M | - |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | - |
| Jeffrey Kindler | M | 68 | 8 years | |
| Henry McKinnell | M | 81 | 8 years | |
| Albert Marchio | M | 72 |
Edge Therapeutics, Inc.
 Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 4 years |
| Kevin Koch | M | 63 | 15 years | |
| Bruce Goldsmith | M | 58 | 2 years | |
| Robert Macdonald | M | 62 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 9 years |
| George A. Lorch | M | 82 | 15 years | |
| Christiana Stamoulis | F | 53 | 4 years | |
| David Shedlarz | M | 75 | 31 years | |
| Robert Azelby | M | 56 | 3 years | |
| Dennis Ausiello | M | 78 | 13 years | |
| Paul Fitzhenry | M | 63 | 4 years | |
| Daniel J. Estes | M | 43 |
University of Michigan
| 4 years |
| Jonathan Emms | M | - | 20 years | |
| Gabriel Andres Thoumi | M | - |
University of Michigan
| 3 years |
| Yasmin Masithela | F | 50 |
University of Cape Town
| 5 years |
| Alan Levin | M | 62 | 20 years | |
| James B. Bucher | M | 59 | - | |
| Nicholas B. Lydon | M | 67 |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | 3 years |
| Kurt Conti | M | 61 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 8 years |
| W. Middlekauff | M | 63 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | - |
| Dana George Mead | M | 88 | 12 years | |
| John L. Zabriskie | M | 85 | 12 years | |
| Samantha Sacks | F | - |
University of Cape Town
| 4 years |
| Leone Patterson | F | 61 | 2 years | |
| Andrew Einhorn | M | 64 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 91 | 91.00% |
| United Kingdom | 7 | 7.00% |
| South Africa | 2 | 2.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Liam Ratcliffe
- Personal Network
